Literature DB >> 32116107

Up-regulated microRNA-411 or declined RIPK1 inhibits proliferation and promotes apoptosis of synoviocytes in rheumatoid arthritis mice via decreased NF-κB pathway.

Yijiang Huang1,2, Kaizhe Chen2,3, Huachen Yu1,2, Daosen Chen1,2, Lianfu Deng2,3, Yu Zhang1,2, Xinghe Xue1,2, Xiaoyun Pan1,2.   

Abstract

Rheumatoid arthritis (RA) is a chronic and inflammatory synovitis systemic disease. Due to the unknown pathogenesis, this study was to investigate the effect of microRNA (miR)-411 on apoptosis and joint function of synoviocytes in RA mice via RIPK1-mediated NF-κB signaling pathway. The collagen-induced arthritis model mice were induced via collagen type II and Freund's adjuvant. The mice were injected with miR-411 mimics, si-RIPK1 or miR-411 mimics + oe-RIPK1 to figure out their roles in cell apoptosis and inflammation of synovial tissues. Synoviocytes were grouped as in animal experiments. Proliferation and apoptosis of synoviocytes were detected upon treatment with overexpressed miR-411 and silenced RIPK1. The expression of miR-411, RIPK1 and NF-κB in synovial tissues and synoviocytes of RA mice was detected by RT-qPCR and Western blot analysis. Poorly expressed miR-411, and highly expressed NF-κB and RIPK1 existed in synovial tissue and synoviocytes of RA. Additionally, it was found that si-RIPK1 decreased NF-κB expression, and miR-411 mimics decreased both RIPK1 and NF-κB. MiR-411 had a targeted relationship with RIPK1. si-RIPK1 or miR-411 mimics promoted cell apoptosis and strained inflammation in synovial tissues of mice with RA. Overexpressed miR-411 or silencing RIPK1 inhibited the proliferation and promoted apoptosis of synoviocytes of RA mice. Up-regulation of miR-411 or down-regulation of RIPK1 had a certain inhibitory effect on RA. This study suggests that up-regulated miR-411 or down-regulated RIPK1 promoted apoptosis and inhibited proliferation of synoviocytes of RA mice, which may be related to the inhibition of NF-κB activation.

Entities:  

Keywords:  RIPK1; Rheumatoid arthritis; microrna-411

Mesh:

Substances:

Year:  2020        PMID: 32116107      PMCID: PMC7145324          DOI: 10.1080/15384101.2020.1717033

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  23 in total

1.  Exploration of the serum metabolite signature in patients with rheumatoid arthritis using gas chromatography-mass spectrometry.

Authors:  Jia Zhou; Jiao Chen; Changfeng Hu; Zhijun Xie; Haichang Li; Shuangshuang Wei; Dawei Wang; Chengping Wen; Guowang Xu
Journal:  J Pharm Biomed Anal       Date:  2016-02-04       Impact factor: 3.935

Review 2.  New therapies for treatment of rheumatoid arthritis.

Authors:  Josef S Smolen; Daniel Aletaha; Marcus Koeller; Michael H Weisman; Paul Emery
Journal:  Lancet       Date:  2007-12-01       Impact factor: 79.321

3.  Immunoexpression of canonical Wnt and NF-κB signaling pathways in the temporomandibular joint of arthritic rats.

Authors:  Luane Macêdo de Sousa; Joana Maria Dos Santos Alves; Conceição da Silva Martins; Karuza Maria Alves Pereira; Paula Goes; Delane Viana Gondim
Journal:  Inflamm Res       Date:  2019-08-01       Impact factor: 4.575

4.  miR-411 contributes the cell proliferation of lung cancer by targeting FOXO1.

Authors:  Zhiju Zhao; Limei Qin; Shu Li
Journal:  Tumour Biol       Date:  2015-11-17

5.  MiR-411 suppresses the development of bladder cancer by regulating ZnT1.

Authors:  Yang Liu; Tao Liu; Hongwei Jin; Lei Yin; Hongyuan Yu; Jianbin Bi
Journal:  Onco Targets Ther       Date:  2018-12-04       Impact factor: 4.147

6.  Oncogenic microRNA-411 promotes lung carcinogenesis by directly targeting suppressor genes SPRY4 and TXNIP.

Authors:  Caiyan Zhang; Huimin Wang; Xiaomin Liu; Yanping Hu; Lei Ding; Xing Zhang; Qiangling Sun; Yanli Li
Journal:  Oncogene       Date:  2018-11-02       Impact factor: 9.867

7.  MiR-613 inhibits proliferation and invasion and induces apoptosis of rheumatoid arthritis synovial fibroblasts by direct down-regulation of DKK1.

Authors:  Liang Liu; Yanhua Zuo; Yan Xu; Zongfang Zhang; Ying Li; Jie Pang
Journal:  Cell Mol Biol Lett       Date:  2019-04-19       Impact factor: 5.787

8.  Characterization of T-Cell Receptor Repertoire in Patients with Rheumatoid Arthritis Receiving Biologic Therapies.

Authors:  Che-Mai Chang; Yu-Wen Hsu; Henry Sung-Ching Wong; James Cheng-Chung Wei; Xiao Liu; Hsien-Tzung Liao; Wei-Chiao Chang
Journal:  Dis Markers       Date:  2019-07-07       Impact factor: 3.434

9.  Clinical Characteristics in Patients with Rheumatoid Arthritis: Differences between Genders.

Authors:  M Intriago; G Maldonado; J Cárdenas; C Ríos
Journal:  ScientificWorldJournal       Date:  2019-07-03

10.  Interferon-gamma regulates inflammatory cell death by targeting necroptosis in experimental autoimmune arthritis.

Authors:  Seung Hoon Lee; Ji Ye Kwon; Se-Young Kim; KyoungAh Jung; Mi-La Cho
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

View more
  4 in total

Review 1.  Indigenous Nigeria medicinal herbal remedies: A potential source for therapeutic against rheumatoid arthritis.

Authors:  Uche O Arunsi; Ogbuka E Chioma; Paschal E Etusim; Solomon E Owumi
Journal:  Exp Biol Med (Maywood)       Date:  2022-06-16

Review 2.  The non-coding RNA interactome in joint health and disease.

Authors:  Shabana A Ali; Mandy J Peffers; Michelle J Ormseth; Igor Jurisica; Mohit Kapoor
Journal:  Nat Rev Rheumatol       Date:  2021-09-29       Impact factor: 20.543

Review 3.  Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis.

Authors:  Jie Huang; Xuekun Fu; Xinxin Chen; Zheng Li; Yuhong Huang; Chao Liang
Journal:  Front Immunol       Date:  2021-07-09       Impact factor: 7.561

4.  MicroRNA-411-3p inhibits bleomycin-induced skin fibrosis by regulating transforming growth factor-β/Smad ubiquitin regulatory factor-2 signalling.

Authors:  Ziyan Zhang; Xuemin Gao; Yang He; Yumeng Kang; Fuyu Jin; Yaqian Li; Tian Li; Zhongqiu Wei; Shifeng Li; Wenchen Cai; Na Mao; Shan Wang; Heliang Liu; Fang Yang; Hong Xu; Jie Yang
Journal:  J Cell Mol Med       Date:  2021-11-15       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.